BMC Cancer · 2021 · 28 citations · 29 references
MedicineGeneticsOncologyCancer GeneticsMolecular OncologyNeoplasiaCancer Molecular PathologyColorectal CancerMalignant NeoplasmsMolecular Classification Of TumorsOncogene MutationsRas Family OncogenesAberrant Ras ActivationBraf V600 MutationsBraf V600e MutationColorectal Cancer PrognosisOncogenic Driver MutationsOncogenic Ras MutationsOncogenic Receptor Tyrosine Kinase Mutations
Abstract Background RAS /BRAF V600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with detailed RAS /BRAF V600E -mutant metastatic CRC (mCRC) in Japan. Methods A total of 152 chemotherapy-naïve patients with mCRC were included in this study between August 2018 and July 2019. Tumor samples were collected, and RAS /BRAF V600E status was investigated. RAS /BRAF V600E status was examined using a MEBGEN RASKET-B kit and polymerase chain reaction reverse sequence-specific oligonucleotide method. Results RAS /BRAF V600E mutations were detected in 54% of cases ( KRAS codon 12, 26%; KRAS codon 13, 17%; KRAS non-Exon2, 5%; NRAS , 5%; and BRAF V600E , 7%). BRAF V600E -mutant CRC mainly existed in the right colon, whereas KRAS non-Exon2 and NRAS -mutant CRC was predominantly present in the left colon. KRAS non-Exon2 and NRAS -mutant CRC were associated with shorter survival time than RAS wild-type CRC (hazard ratio [HR], 2.26; 95% confidence interval [CI], 0.64–8.03; p = 0.19; HR, 2.42; 95% CI, 0.68–8.61; p = 0.16) and significantly shorter overall survival than KRAS Exon2-mutant CRC (HR, 3.88; 95% CI, 0.92–16.3; p = 0.04; HR, 4.80; 95% CI, 1.14–20.2; p = 0.02). Conclusions In our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS /BRAF V600E -mutant mCRC in Japan.
29
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text
Medicine, Oncology, Pharmacology +17
Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer
Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +15